Optimizing a human monoclonal antibody for better neutralization of SARS-CoV-2

Optimizing a human monoclonal antibody for better neutralization of SARS-CoV-2

Abstract SARS-CoV-2 has largely evolved to resist antibody pressure, with each successive viral variant becoming more and more resistant to serum antibodies in the population. This evolution renders all previously authorized anti-spike therapeutic monoclonal antibodies inactive, and it threatens the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qian Wang, Yicheng Guo, Ryan G. Casner, Jian Yu, Manoj S. Nair, Jerren Ho, Eswar R. Reddem, Ian A. Mellis, Madeline Wu, Chih-Chen Tzang, Hsiang Hong, Yaoxing Huang, Lawrence Shapiro, Lihong Liu, David D. Ho
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-07-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-025-61472-z
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages
by: Qian Wang, et al.
Published: (2024-12-01)

Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2
by: Mengxiao Luo, et al.
Published: (2023-12-01)

Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC
by: Qian Wang, et al.
Published: (2025-04-01)

Impaired potency of neutralizing antibodies against cell–cell fusion mediated by SARS-CoV-2
by: Qian Wang, et al.
Published: (2023-12-01)

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination
by: Sho Iketani, et al.
Published: (2021-01-01)

Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus
by: Fan Yang, et al.
Published: (2020-01-01)

Cross-neutralization ability of anti-MERS-CoV monoclonal antibodies against a variety of merbecoviruses
by: Lin Pan, et al.
Published: (2025-07-01)

Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment.
by: Elizabeth S Munroe, et al.
Published: (2025-01-01)

Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment
by: Elizabeth S. Munroe, et al.
Published: (2025-01-01)

Experience in the use of neutralizing monoclonal antibodies in kidney transplant recipients with COVID-19
by: I. G. Kim, et al.
Published: (2023-04-01)

Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review
by: Sharana Mahomed, et al.
Published: (2025-04-01)

Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in Nicotiana benthamiana
by: Nuttapat Pisuttinusart, et al.
Published: (2024-12-01)

Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders
by: Stephanie Maciuba, et al.
Published: (2023-12-01)

Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
by: Ignacio Melero, et al.
Published: (2023-10-01)

Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody
by: Isabella Hrabal, et al.
Published: (2025-03-01)

Therapeutic potential of the neutralizing monoclonal antibody 45G3 against encephalomyocarditis virus
by: Yanfang Zhang, et al.
Published: (2025-01-01)

Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies.
by: Bongiwe Ndlovu, et al.
Published: (2025-06-01)

Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies.
by: Evgeny Shmelkov, et al.
Published: (2014-01-01)

Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody.
by: Xiaohua Ye, et al.
Published: (2016-03-01)

Correction: Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody
by: Isabella Hrabal, et al.
Published: (2025-05-01)

Neutralizing monoclonal antibodies improve biodistribution of intravenously administered oncolytic adenovirus in human CD46-transgenic mice.
by: Masahisa Hemmi, et al.
Published: (2025-01-01)

Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews
by: Xinglong Liu, et al.
Published: (2024-12-01)

Lessons learned and real-world insights from implementing neutralizing monoclonal antibody programs for treatment of COVID-19
by: Nalini Ambrose, et al.
Published: (2024-01-01)

A highly neutralizing human monoclonal antibody targeting a novel linear epitope on staphylococcal enterotoxin B
by: Hongyin Fan, et al.
Published: (2024-12-01)

Cell-based high-content approach for SARS-CoV-2 neutralization identifies unique monoclonal antibodies and PI3K pathway inhibitors
by: Carly R. Cabel, et al.
Published: (2025-05-01)

Neutralizing and enhancing monoclonal antibodies in SARS-CoV-2 convalescent patients: lessons from early variant infection and impact on shaping emerging variants
by: Frédéric Coutant, et al.
Published: (2024-12-01)

A human monoclonal antibody isolated from Japanese encephalitis virus vaccine-vaccinated volunteer neutralizing various flaviviruses
by: Dong Chen, et al.
Published: (2024-12-01)

Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex
by: Minoru Tada, et al.
Published: (2023-12-01)

Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
by: Yuxin Chen, et al.
Published: (2021-01-01)

Two periodic solutions of neutral difference equations modelling physiological processes
by: Jun Wu, et al.
Published: (2006-01-01)

Characterization of the Binding and Inhibition Mechanisms of a Novel Neutralizing Monoclonal Antibody Targeting the Stem Helix Region in the S2 Subunit of the Spike Protein of SARS-CoV-2
by: Selene Si Ern Tan, et al.
Published: (2025-06-01)

Development and evaluation of a recombinant monoclonal human antibody with virus-neutralizing activity against the F glycoprotein of respiratory syncytial virus
by: Sergey A. Klotchenko, et al.
Published: (2024-12-01)

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.
by: Davide Corti, et al.
Published: (2010-01-01)

Methadone or buprenorphine: which is the better analgesic for feline ovariohysterectomy?
by: Isobel Lawrence
Published: (2024-11-01)

Is It Better to Take a Proton Pump Inhibitor before a Meal for Helicobacter pylori Eradication?
by: Tae Ho Kim
Published: (2018-06-01)

Control Problems for Semilinear Neutral Differential Equations in Hilbert Spaces
by: Jin-Mun Jeong, et al.
Published: (2014-01-01)

Isolation and Characterization of E8 Monoclonal Antibodies from Donors Vaccinated with Recombinant Vaccinia Vaccine with Efficient Neutralization of Authentic Monkeypox Virus
by: Yutao Shi, et al.
Published: (2025-04-01)

A novel neutralizing monoclonal antibody recognizes a linear antigenic epitope of the spike protein of swine acute diarrhoea syndrome coronavirus
by: Lin Zhang, et al.
Published: (2024-11-01)

WCN24-1318 The characteristics of IgM variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits
by: Lihong Bu, et al.
Published: (2024-04-01)

Experiences of recently diagnosed urban COVID-19 outpatients: A survey on patient worries, provider-patient interactions, and neutralizing monoclonal antibody treatment.
by: Lindsey E Fish, et al.
Published: (2025-01-01)